학술논문
308 Incremental improvements after switching from dupilumab (DUPI) to upadacitinib (UPA) in the Heads Up open-label extension (OLE) study
Document Type
Abstract
Author
Source
In Journal of Investigative Dermatology August 2022 142(8) Supplement:S53-S53
Subject
Language
ISSN
0022-202X